Precision Medicine Quarterly

SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics

2022-06-16T20:33:13-05:00June 16th, 2022|

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced it has signed a licensing agreement with OncoHost, a global leader in next-generation precision oncology for personalized cancer therapy. As part of the agreement, OncoHost will license SomaLogic’s SomaScan® Platform to develop proteomics tests for its PROphet® diagnostic system, designed to predict patient [...]

Tempus Announces Research Collaboration with Intermountain Healthcare to Advance Precision Oncology Research

2022-06-16T20:14:04-05:00June 16th, 2022|

Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Intermountain Healthcare, a Utah-based, nonprofit healthcare system, which leverages genomic testing and data analytics to advance research intended to improve outcomes for cancer patients. Intermountain Healthcare is leveraging Tempus’ solid tumor/normal genomic test, xT, to generate whole transcriptomic data on [...]

Halo Diagnostics to Offer Genomic Testing Cooperative Genomic Profiling Tests

2022-06-16T20:06:56-05:00June 16th, 2022|

Halo Diagnostics said on Tuesday that it has signed an agreement to offer Genomic Testing Cooperative's (GTC) cancer genomic profiling assays to its patients. Menlo Park, California-based Halo — formerly Desert Medical Imaging — provides diagnostic imaging and related services for cancer and other conditions at facilities in California, Texas, and Florida. Under the [...]

Thermo Fisher Scientific Receives CE-IVD Mark for NGS Aneuploidy Diagnostic Software Workflows

2022-06-16T20:04:58-05:00June 16th, 2022|

Thermo Fisher Scientific said on Wednesday that it has received CE-IVD marking for its Ion Torrent Reporter Software Aneuploidy Dx Workflows. The CE-IVD Mark covers two workflows: low-pass whole-genome aneuploidy Dx w1.0 and low-pass whole-genome aneuploidy Mosaic Dx 1.0. These workflows are to be used in combination with general, non-in vitro diagnostic products, including [...]

Allen Institute, Google Release Multiomic Immunology Research Portal

2022-06-16T17:37:13-05:00June 16th, 2022|

The Allen Institute for Immunology this month publicly introduced a new data-sharing portal called the Human Immune System Explorer (HISE) that the organization hopes will unleash a new wave of longitudinal immunology studies. Initially developed as an informatics framework to support the Seattle-based institute and its partners, HISE is now being released to the [...]

Imagia Canexia Health Garners CE-IVD Mark for Comprehensive Cancer Testing Platform

2022-06-16T17:33:32-05:00June 16th, 2022|

Imagia Canexia Health on Wednesday said it is ready to deploy its comprehensive cancer testing platform in Europe after having fulfilled the requirements for CE-IVD marking. The Imagia Canexia Health Insights Platform (ICHIP) analyzes patients' targeted next-generation sequencing data and generates a report with therapeutic and clinical trial information. Patients first have their blood [...]

Paige, Janssen Partner on Bladder Cancer Dx

2022-06-16T17:32:07-05:00June 16th, 2022|

Paige on Wednesday said that it will work with Janssen Research & Development to assess the ability of a screening tool developed by Janssen to predict the presence of fibroblast growth factor receptor (FGFR) genes in patients with advanced bladder cancer. The test relies on screening hematoxylin and eosin (H&E)-stained slides and is aimed [...]

Kidney Disease Targets Uncovered in Integrated Omics Analysis

2022-06-16T13:43:55-05:00June 16th, 2022|

A University of Pennsylvania-led team has identified hundreds of kidney disease risk loci, bringing in additional epigenetic, gene expression, single-cell, and functional data to dig into some of the genes, pathways, and cell types behind the genetic associations. "[W]e report a comprehensive analysis of the genetic determinant of human kidney function and show the [...]

Rady Children’s Institute for Genomic Medicine Partners With Inozyme Pharma on NGS Newborn Screening

2022-06-16T13:42:36-05:00June 16th, 2022|

Inozyme Pharma said on Thursday that it has partnered with the Rady Children's Institute for Genomic Medicine (RCIGM) on whole-genome sequencing-based newborn screening for genetic diseases. Through the BeginNGS consortium, the partners will use whole-genome sequencing-based newborn screening to identify infants affected by ENPP1 deficiency and ABCC6 deficiency. Inozyme is developing a novel therapy, [...]

Go to Top